LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

Search

McKesson Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

959.63 0.42

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

946.28

Max

958.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

40M

1.3B

Pardavimai

3B

106B

P/E

Sektoriaus vid.

26.954

110.024

Dividendų pajamingumas

0.33

Pelno marža

1.177

Darbuotojai

43,000

EBITDA

374M

1.8B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+3.42% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.33%

2.26%

Kitas uždarbis

2026-05-07

Kitas dividendų mokėjimo data

2026-04-01

Kita Ex Dividend data

2026-03-02

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

10B

115B

Ankstesnė atidarymo kaina

959.21

Ankstesnė uždarymo kaina

959.63

Naujienos nuotaikos

By Acuity

54%

46%

288 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

McKesson Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-24 23:07; UTC

Uždarbis

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026-02-24 23:01; UTC

Uždarbis

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026-02-24 22:59; UTC

Uždarbis

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026-02-24 22:42; UTC

Uždarbis

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026-02-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026-02-24 23:46; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026-02-24 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026-02-24 23:30; UTC

Rinkos pokalbiai

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026-02-24 23:20; UTC

Rinkos pokalbiai

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026-02-24 23:20; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-24 23:16; UTC

Uždarbis

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026-02-24 23:13; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026-02-24 23:12; UTC

Uždarbis

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026-02-24 23:10; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026-02-24 23:10; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026-02-24 23:08; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026-02-24 23:07; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026-02-24 22:52; UTC

Uždarbis

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026-02-24 22:46; UTC

Uždarbis

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026-02-24 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Warner Receives New Bid From Paramount -- 3rd Update

2026-02-24 22:29; UTC

Uždarbis

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026-02-24 22:28; UTC

Uždarbis

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026-02-24 22:27; UTC

Uždarbis

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026-02-24 22:27; UTC

Uždarbis

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026-02-24 22:25; UTC

Uždarbis

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026-02-24 22:24; UTC

Uždarbis

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026-02-24 22:23; UTC

Uždarbis

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026-02-24 22:22; UTC

Uždarbis

Woolworths Interim Dividend 45 Australian Cents/Share

2026-02-24 22:22; UTC

Uždarbis

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

2026-02-24 22:21; UTC

Uždarbis

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Akcijų palyginimas

Kainos pokytis

McKesson Corp Prognozė

Kainos tikslas

By TipRanks

3.42% į viršų

12 mėnesių prognozė

Vidutinis 990.1 USD  3.42%

Aukščiausias 1,107 USD

Žemiausias 885 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines McKesson Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

9

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

681.92 / 707.28Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

No Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

288 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę McKesson Corp

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
help-icon Live chat